MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Net Income 2011-2026 | BIO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -716 M | 350 M | -3.63 B | 4.25 B | 3.81 B | 1.76 B | 366 M | 122 M | 28.1 M | 113 M | 88.8 M | 77.8 M | 164 M | 178 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.25 B | -3.63 B | 498 M |
Quarterly Net Income Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 318 M | 64 M | 653 M | -2.17 B | 384 M | 106 M | -1.16 B | 69 M | - | -163 M | -925 M | -3.37 B | -1.57 B | 3.93 B | 914 M | 977 M | 839 M | 1.31 B | 966 M | 686 M | 554 M | -259 M | 599 M | 865 M | -828 M | 269 M | 268 M | 657 M | 82.7 M | 22.1 M | 5 M | 12.4 M | -18.7 M | 17.1 M | 16.6 M | 11 M | 49.5 M | 17.4 M | 28.4 M | 17.8 M | 39 M | 11.5 M | 31.6 M | 6.7 M | 30.1 M | -7.1 M | 34.6 M | 20.2 M | 42 M | 42.6 M | 48.3 M | 31 M | 59.2 M | 45.9 M | 40 M | 33 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.93 B | -3.37 B | 86.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B |  USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
FONAR Corporation
FONR
|
12.4 M | $ 18.58 | -0.11 % | $ 122 M | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 12.0 | -0.58 % | $ 1.62 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 90.43 | 2.07 % | $ 12.2 B | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 9.11 | -2.88 % | $ 258 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
113 M | $ 36.38 | -0.98 % | $ 5.42 K | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 1.8 | -5.53 % | $ 1.09 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 9.25 | -0.64 % | $ 712 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 54.48 | 0.63 % | $ 1.6 B | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.03 | 3.35 % | $ 17.4 M | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 85.52 | -0.13 % | $ 2.97 B | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.77 | -2.04 % | $ 69 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.82 | -0.75 % | $ 371 M | USA |
 |
Medtronic PLC
MDT
|
4.66 B | $ 86.33 | 0.06 % | $ 111 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-21.2 M | $ 3.42 | -1.16 % | $ 128 M |  France |
 |
Myomo
MYO
|
-15.6 M | $ 0.67 | -4.85 % | $ 28 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Align Technology
ALGN
|
421 M | $ 168.21 | -2.13 % | $ 12.6 B | USA |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 11.81 | 0.34 % | $ 468 M |  Curacao |
 |
AxoGen
AXGN
|
-15.7 M | $ 31.01 | -4.99 % | $ 1.43 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 204.23 | 0.36 % | $ 14.4 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.76 | 9.09 % | $ 7.65 M | USA |
 |
Smith & Nephew plc
SNN
|
524 M | $ 31.76 | -2.67 % | $ 23.8 B |  Britain |
 |
Butterfly Network
BFLY
|
-72.5 M | $ 4.02 | -2.66 % | $ 851 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
849 M | $ 331.18 | -0.34 % | $ 127 B | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 24.16 | -1.67 % | $ 553 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.61 | 3.37 % | $ 38 M | USA |
 |
TELA Bio
TELA
|
-38.8 M | $ 0.7 | 11.11 % | $ 32.9 M | USA |
 |
TransMedics Group
TMDX
|
190 M | $ 107.91 | 2.97 % | $ 3.67 B | USA |
 |
Tandem Diabetes Care
TNDM
|
-589 K | $ 18.66 | -2.66 % | $ 1.27 B | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 9.68 | -0.21 % | $ 347 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.89 B | $ 61.33 | -2.01 % | $ 90.8 B | USA |
 |
Alphatec Holdings
ATEC
|
-143 M | $ 11.09 | 1.05 % | $ 1.66 B | USA |